International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

Impact the Antibiotics Resistance of Enterobacter spp. in Cancer patients

Fattma A Ali, Ahmed Akil Khudhair Al-Daoody, Bashdar Mahmud Hussen, Shayma Hatam, Naba Mheddin Ekhlas, Sarhad, Rawan Sabir, Yaqub Aziz

College of Health Sciences/Hawler Medical University. Kurdistan Region, Erbil, Iraq; Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Kurdistan Region, Erbil, Iraq

Article Information

Volume / Issue4 / 1 (January-March 2023)
Pages40-48
AccessOpen Access

Publication Timeline

  • Received15 February 2023
  • Accepted16 March 2023

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

Background: Infection is a continuous problem in cancer patient especially in developing country, multi-drug resistance of Enterobacter spp. are among the most frequent complication in Immunocompromised cancer patients and pose the greatest risk to Immunocompromised cancer patient.

Objectives: Our study aimed to carry out a retrospective study on Enterobacter spp. isolated from various clinical samples among cancer patient in Erbil city and analyze its epidemiology and antibiotics susceptibility pattern test and multi-drug resistance.

 Materials and Methods: A total of 467 from 2016 until 2020 Enterobacter spp. were isolated from 5 clinical samples (Urine, Wound and Ear swabs, Blood and Stool) from patient attending Nanakali Hospital and from both male and female. Only 32 cases had been identified as Enterobacter spp. isolates which was identified by using macroscopical, biochemical tests and Vitek 2 compact system. Also antibiotic susceptibility test was performed by Vitek 2 compact on 19 antibiotics.

Results: Only 32 Enterobacter isolates were isolated from 467 samples distribution according to their source of isolation in cancer patient. Urinary tract infections is the most common in our study followed by otitis media infection, and Skin-wound infection, Blood stream infection, the percentage of females infected with Enterobacter spp. were more than the males, females being 20/467(4.2%) and males being 12/467(2.5%), after 2016 infections by Enterobacter spp. was increased in over than 31 years old people being 9/15(60%) in total, from 2016-2020 Enterobacter spp. infected patients with solid tumor type was 16/32(50%) and leukemia was 9/32(28%) and multiple myeloma was 7/32(22%)for each, Although (Imipenem, Amikicin, Levofloxacin, Ticarcillin/clavulanic acid, Ceftazidime, Amoxicillin, Cephalexin) can be considered as effective agents toward multi-drug resistance strains for empirical antibiotic therapy in cancer patients, Enterobacter Spp. isolates had resistance to 11 antibiotics.

Conclusions: The study findings showed a significant distribution of multi-drug resistance Enterobacter spp. which may increase the burden of healthcare-associated infections in cancer patients. Moreover, mechanisms of resistance should also be investigated for better characterization antibiotic-resistant of Enterobacter spp isolates.

 

Keywords

Enterobacter sppCancer patientmulti-drug resistance

References

  1. Adnan SG, Khaled AM, Abdul Baki AR, Hassan AS and Naelash AA. Urinary tract infection among renal transplant recipients in Yemen. Plos One. 2015; 10(12):10-1371. [Google Scholar][Crossref]
  2. Ahmed SS, Ali FA. Detection Of Esbl, Ampc and metallo beta- lactamase mediated resistance in gram-negative bacteria isolated from women with genital tract infection1. European Scientific Journal, 2014, 10(9). ISSN: 1857-7881 (Print) e - ISSN 1857- 7431. [Google Scholar][Crossref]
  3. Anderson and Cindy. Great Adventures in the Microbiology Laboratory (7th ed.). Pearson, 2013 175-176. ISBN 978-1-269-39068-2. [Google Scholar][Crossref]
  4. Ashour HM, A El-Sharif. Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients, Journal of Translational Medicine. 2009; 7(1):14. [Google Scholar][Crossref]
  5. Ali FA, Sabah HZ, Khalis NA, Hussien PR, Ghanim SM. Impact the Antibiotic Resistance for Staphylococcus aureus in Hospitalized Cancer Patients in Erbil Governate, Iraq. South Asian Journal of Research in Microbiology. 2022; 14(3-4):40-51. [Google Scholar][Crossref]
  6. Ali FA, Redar S, Shekh AS, Sami S, Akram P. Microbiological study of distribution of extend spectrum beta lactamase among gram negative bacteria isolated from different clinical samples in Erbil City/Iraq. Adv J Pharm Life sci. Res. 2019 7(1):38-53. ISSN 2454 3535 (On-line) www.ajplronline.org. [Google Scholar][Crossref]
  7. Ali FA, Al Sudani SK, Hassan GH, Bakir SH. Risk Factors of Multidrug-resistant Klebsiella spp. in Hospitalized Cancer Patients in Erbil Governate, Iraq. The Journal of Research on the Lepidoptera. 2020; 51(3):123-140. [Google Scholar][Crossref]
  8. Bakir SH, Ali FA. Evalution of multi-drug resistance and β-lactamase production in throat infected by gram positive bacteria. European journal of pharmaceutical and medical research, EJPMR. 2016; 3(2):68-76. [Google Scholar][Crossref]
  9. Bornet C, Saint N, Fetnaci L, Dupont M, Davin-Régli A, Bollet C, et al. Omp35 a new Enterobacter aerogenes porin involved in selective susceptibility to cephalosporins. Antimicrob. Agents Chemother. 2004; International Journal of Medical and All Body Health Research www.allmedicaljournal.com 48:2153-2158 10.1128/AAC.48.6.2153-2158. [Google Scholar][Crossref]
  10. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009: 48:1-12. doi:10.1086/595011. [Google Scholar][Crossref]
  11. Carter MQ, Pham A, Huynh S, He X. Complete genome sequence of a Shiga toxin-producing Enterobacter cloacae clinical isolate. 2017. Genome Announc 5:e00883-17. doi:10.1128/genomeA.00883-17. [Google Scholar][Crossref]
  12. Cattaneo C, Quaresmini G, Casari S, Capucci M, Micheletti M, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother. 2008; 61:721-728. [Google Scholar][Crossref]
  13. Cheesbourgh M. District laboratory practice in tropical countries part II, 2nd ed. Cambridge University Press, 2006, New York. [Google Scholar][Crossref]
  14. Choi SH, Lee JE, Park SJ, Lee SO, Jeong JY, Kim MN, et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother. 2008; 52:995-1000. [Google Scholar][Crossref]
  15. Davin-Regil A, Philippe Lavigne J, Marie Pages J. Enterobacter spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance. Clinical Microbiology Reviews. 2019; 32(4):2. [Google Scholar][Crossref]
  16. Davin-Regli A, Pagès JM. Cross-resistance between biocides and antimicrobials: an emerging question. Rev. Sci. Tech. 2012; 31:89-104. [Google Scholar][Crossref]
  17. Eldomany R, Abdelaziz NA. Characterization and Antimicrobial susceptibility of gram negative bacteria isolated from cancer patients on chemotherapy in Egypt. Imed pub Journals. 2011; 2(6):2. [Google Scholar][Crossref]
  18. Fair R.J, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect. Med. Chem. 2014; 6:25-64. [Google Scholar][Crossref]
  19. Fraser SL. Enterobacter infections. Department of Medicine, Drug & Diseases, 2019, 18. [Google Scholar][Crossref]
  20. Gebremichael S, Teklu DSh, Legese MH, Dseta K. Extended-spectrum Beta-lactamase and AmpC beta-lactamases producing gram negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia. PLoS One Journal, 2020, 15(11). [Google Scholar][Crossref]
  21. Ghonaim RA, Elgohary TA. The Rate of Extended-Spectrum B-Lactamases among Commonly Isolated Enterobacteriaceae in Cancer Patients in Zagazig University Hospitals. Journal of Microbiology Research. 2017; 7(2):31-38. [Google Scholar][Crossref]
  22. Gualerzi CO, Brandi L, Fabbretti A, Pon CL (ed), Antibiotics-targets, mechanims and resistance. Wiley-VCH Verlag GmbH & Co. KGaA Publications, Weinheim, Germany. [Google Scholar][Crossref]
  23. Gudiol and Carratala. Antibiotic resistance in cancer patients. Expert Rev. Anti-Infect. Ther. 2014; 12(8):1003-1016. [Google Scholar][Crossref]
  24. Guinan JL, McGuckin M, Nowell PC. Management of health-care– associated infections in the oncology patient. Oncology (Williston Park). 2003, 17:415-420. [Google Scholar][Crossref]
  25. Hong YK, Lee JY, Ko KS. Colistin resistance in Enterobacter spp. isolates in Korea. J Microbiol. 2018; 56(6):435-440. [Google Scholar][Crossref]
  26. Huh K, In-Kang C, Kim J, Young Cho S, Eun Ha Y, Jeong Joo E, et al. All-risk factors and treatment outcomes of bloodstream infection caused by extended-spectrum cephalosporin-resistant Enterobacter species in adults with cancer. Diagnostic Microbiology and Infectious Disease. 2014; 78(2):172-7. [Google Scholar][Crossref]
  27. Isendahl J, Turlej-Rogacka C, Manjuba A, Rodrigues CG. Giske, Naucle´r. Fecal carriage of ESBLProducing E. coli and K. pneumoniae in children in Guinea Bissau: a hospital-based cross-sectional study. PLoS.One. 2012; 7:1-6. [Google Scholar][Crossref]
  28. Jawad SM. Molecular Study of Enterobacteriaceae Associated with Colorectal Cancer. Ph.D thesis. University of Kufa. Department of Biology. 2020. Kufa. Iraq. [Google Scholar][Crossref]
  29. Jawetz E, Melnick, Adelberg̕s E. Medical microbiology. 24th edition. McGraw Hill Companies. USA. 2007. [Google Scholar][Crossref]
  30. Kader AA, Kamath KA, Dass SM. Accelerated detection of extended-spectrum beta lactamases in clinical isolates of Enterobacteriaceae. Br J Biomed Sci. 2006; 63:151-154. [Google Scholar][Crossref]
  31. Kamel NA, El-tayeb WN, El-Ansary MR, Mansour MT, Aboshanab KM. Phenotypic screening and molecular characterization of carbapenemase-producing Gram-negative bacilli recovered from febrile neutropenic pediatric cancer patients in Egypt. Plos One Journal, 2018. [Google Scholar][Crossref]
  32. Kasse M, Baars B, Friedrich S, Szabados F, Gatermann SG. Performance of MicroScan WalkAway and Vitek 2 for Detection of Oxacillin Resistance in a Set of Methicillin- Resistant Staphylococcus aureus Isolates with Diverse Genetic Backgrounds. Journal of Clinical Microbiology. 2009; 47(8):2623-2625. [Google Scholar][Crossref]
  33. Kim SJ, Park KH, Chung JW, Sung H, Choi SH. Prevalence and impact of extended-spectrum β-lactamase production on clinical outcomes in cancer patients with Enterobacter species bacteremia. Korean Journal International Medication. 2014; 29(5):637-646. [Google Scholar][Crossref]
  34. Klastersky J, Aoun M. Opportunistic infections in patients with cancer. Ann Oncol. 2004; 15:329-335. [Google Scholar][Crossref]
  35. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clinical Infection Disease Journal. 2000; 31(4):131-138. [Google Scholar][Crossref]
  36. Kurtaran B, Candevir A, Tasova Y, Kibar F, Inal AS, et al. Hospital-acquired bloodstream infections in cancer patients between 2005 and 2007 in a Turkish university hospital. Arch Clin Microbiol. 2010; 1:2. doi: 10:3823/205 (https://www.acmicrob.com). [Google Scholar][Crossref]
  37. Lee SO, Kim YS, Kim BN, Kim MN, Woo JH, Ryu J. Impact of previous use of antibiotics on development of resistance to extended spectrum cephalosporins in patients with Enterobacter bacteremia. Eur J Clin Microbiol Infect Dis. 2002; 21:577-581. [Google Scholar][Crossref]
  38. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18:268-81. [Google Scholar][Crossref]
  39. Man PDe, Verhoeven BAN, Verbrugh HA, Vos MC, Van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet. 2000; 355:973-8. [Google Scholar][Crossref]
  40. Marín M, Gudiol, Ardanuy C, García-Vidal C, Calvo M, Arnan M, et al. Bloodstream infections in neutropenic patients with cancer: differences between patients with International Journal of Medical and All Body Health Research www.allmedicaljournal.com haematological malignancies and solid tumours. J Infect. 2014; 69:417-423. [Google Scholar][Crossref]
  41. Martinez AFH, Fontal GRG, Mancilla GRC, Yang IV. Enterobacteriaceae bacteremias among cancer patients: an observational cohort study,International Journal of Infectious Diseases. 2013; 17(6):374-378. [Google Scholar][Crossref]
  42. Masi M, Réfregiers M, Pos KM, Pagès JM. Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria. Nat Microbiol. 2017; 2:17001. Doi: 10.1038/nmicrobiol.2017.1. [Google Scholar][Crossref]
  43. Mofid K, Novin E, Roointan S and Forouzanfar MM, Epidemiology and death-related factors of oncology patients in emergency department. Department of Radiation Oncology, Shohodaye Tajrish Hospital, Shahid Beheshti University of Medical sciences, Tehran, Iran. 2016; 4(4):145–150. [Google Scholar][Crossref]
  44. Montes CV, Vilar-Compte D, Velazquez C, Golzarri MF, Cornejo-Juarez P, Larson EL. Risk factors for extended spectrum b-lactamase-producing Escherichia coli versus susceptible E. coli in surgical site infections among cancer patients in Mexico. Surg. Infect. (Larchmt).2014; 15:627-634. [Google Scholar][Crossref]
  45. Morris PG, Hassan T, McNamara M, Hassan A, Wiig R, et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia-a cause for concern. Support Care Cancer. 2008; 16:1085-1088. [Google Scholar][Crossref]
  46. Nadir A, Diop A, Ka R, Faye PM, Dia-Badiane NM, Ndoye B, et al. Infections caused by extended-spectrum beta-lactamases producing Enterobacteriaceae: clinical and economic impact in patients hospitalized in 2 teaching hospitals in Dakar, Senegal. Antimicrobial Resistance & Infection Control, 2016, 5(13). [Google Scholar][Crossref]
  47. Nakasone I, Kinjo T, Yamane N, Kisanuki K, Shiohira CM. Laboratory based evaluation of the colorimetric VITEK 2 Compact System for species identification and of the Advanced Expert System for detection of antimicrobial resistances: VITEK 2 Compact System identification and antimicrobial susceptibility testing. Diagnosis Microbiology Infection Disease Journal. 2007; 58:191-198. [Google Scholar][Crossref]
  48. O’Neill J. Antimicrobials in agriculture and the environment: reducing unnecessary use and waste. The review on antimicrobial resistance. London: Wellcome Trust, 2015. [Google Scholar][Crossref]
  49. Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile genetic elements associated with antimicrobial resistance. Clin Microbiol Rev. 2018; 31:e00088-17. Doi: 10.1128/CMR.00088-17. [Google Scholar][Crossref]
  50. Paterson DL, Bonomo RA. Extended-spectrum b-lactamases: A clinical update. Clin Microbiol Rev. 2005; 18:657-686. [Google Scholar][Crossref]
  51. Paterson DL. Infections due to other members of the Enterobacteriaceae, including management of multidrug-resistant strains. Goldman’s Cecil Medicine. 2012; 2:1874-7.24th ed. Amsterdam: Elsevier; doi: http://dx.doi.org/10.1016/B978-1-4377-1604-7.00313-4. [Google Scholar][Crossref]
  52. Rogers K. Enterobacter. Available from (https://www.britannica.com/science/Enterobacter). Accessed at June.2020. [Google Scholar][Crossref]
  53. Rolston KVI, Yadegarynia D, Kontoyiannis DP, Raad II, Ho DH. The spectrum of gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against gram-positive bacteria isolated from cancer patient. Int J Infect Dis. 2006; 10:223-230. [Google Scholar][Crossref]
  54. Rolston KVI, Bodey GP. Infections in patient with cancer. In: Bast CR, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E (Eds.): Cancer Medicine, 5thEd. Hamilton-London: B.C. Decher Inc., 2000, 2407-2432. [Google Scholar][Crossref]
  55. Safdar A, Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin. 2001; 17:531-570. [Google Scholar][Crossref]
  56. Safdar A, Rodriguez GH, Balakrishnan M, Tarrand JJ, Rolston KVI. Changing trends in etiology of bacteremia in patients with cancer. Eur J Clin Microbiol Infect Dis. 2006; 25:522-526. [Google Scholar][Crossref]
  57. Sanders Jr WE, Sanders CC. Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev. 1997; 10:220-241. [Google Scholar][Crossref]
  58. Schumm K, Lam TBL. Types of urethral catheters for management of short-term voiding problems in hospitalized adults: a short version Cochrane review. National Library of Medicine. 2008; 27(8):738-46. doi: 10.1002/nau.20645. [Google Scholar][Crossref]
  59. Staudinger T, Hospital C, Publique A. Current insights into severe sepsis in cancer patients. Rev Bras Ter Intensiva. 2014; 26:335-8. [Google Scholar][Crossref]
  60. Sung H, Siegel R, Rosenberg P, Jernal A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health. 2019; 4:e137-47. [Google Scholar][Crossref]
  61. Suryanto D, Irawati N, Muni E. Isolation and Characterization of Chintinolytic Bacteria and their potential to inhibit plant Pathogenic Fungi. Microbial. 2011; 5(3):144-148. [Google Scholar][Crossref]
  62. Tenover FC, Williams PP, Stocker S. Accuracy of six antimicrobial susceptibility methods for testing linezolid against Staphylococci and Enterococci. Journal of Clinical Microbiology. 2007; 45:2917-2922. [Google Scholar][Crossref]
  63. Tigabu A, Ferede W, Belay G, Gelaw B. Prevalence of Asymptomatic Bacteriuria and Antibiotic Susceptibility Patterns of Bacterial Isolates among Cancer Patients and Healthy Blood Donors at the University of Gondar Specialized Hospital. International Journal of Microbiology, 2020, 33. [Google Scholar][Crossref]
  64. Valade E, Davin-Regli A, Bolla JM, Pagès JM. Bacterial membrane, a key for controlling drug influx and efflux. In Gualerzi CO, Brandi L, Fabbretti A, Pon CL (ed), Antibiotics-targets, mechanims and resistance. Wiley-VCH Verlag GmbH & Co. KGaA Publications, Weinheim, Germany, 2014, 217-240. [Google Scholar][Crossref]
  65. Vital S. Carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013; 62:165-70. [Google Scholar][Crossref]
  66. Wiegand I, Geiss HK, Mack D, Sturenburg E, Seifert H. Detection of Extended-Spectrum β-Lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. Journal of Clinical Microbiology. 2007; 45:1167-117. [Google Scholar][Crossref]
  67. Yurdakul D, Karatas AY, Sahin F. Enterobacter Strains Might Promote Colon Cancer. Springer Science + Business Media New York. 2015; 71:403-411. [Google Scholar][Crossref]
  68. Zorgani AA, Belgasim Z, Ziglam H, Ghenghesh KS. Antimicrobial Susceptibility Profiles of Gram -Negative Bacilli and Gram-Positive Cocci Isolated from Cancer Patients in Libya. I Med Pub Journals. 2012; 3(3):1-8. [Google Scholar][Crossref]

How to Cite

Ali, F. A., Al-Daoody, A. A. K., Hussen, B. M., Hatam, S., Ekhlas, N. M., Sarhad, Sabir, R., & Aziz, Y. (2023). Impact the Antibiotics Resistance of Enterobacter spp. in Cancer patients. International Journal of Medical and All Body Health Research, 4(1), 40-48.

Ali, Fattma A, et al. "Impact the Antibiotics Resistance of Enterobacter spp. in Cancer patients." International Journal of Medical and All Body Health Research, vol. 4, no. 1, 2023, pp. 40-48.

Ali, F. A., Al-Daoody, A. A. K., Hussen, B. M., Hatam, S., Ekhlas, N. M., Sarhad, Sabir, R. and Aziz, Y. (2023) 'Impact the Antibiotics Resistance of Enterobacter spp. in Cancer patients', International Journal of Medical and All Body Health Research, 4(1), pp. 40-48.

Ali FA, Al-Daoody AAK, Hussen BM, Hatam S, Ekhlas NM, Sarhad, et al. Impact the Antibiotics Resistance of Enterobacter spp. in Cancer patients. International Journal of Medical and All Body Health Research. 2023;4(1):40-48.

Similar Articles

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex ResearchGate BASE

A newly published article may take a few days to appear on these services.